An Open Label Pilot Study to Test the Efficacy and Safety of Recombinant Factor VIIa (rFVIIa, NovoSeven) in the Treatment of Refractory Hemorrhagic Cystitis Following High Dose Chemotherapy

Trial Profile

An Open Label Pilot Study to Test the Efficacy and Safety of Recombinant Factor VIIa (rFVIIa, NovoSeven) in the Treatment of Refractory Hemorrhagic Cystitis Following High Dose Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Eptacog alfa (Primary)
  • Indications Haemorrhagic cystitis
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 14 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top